“We are laser focused on high-quality clinical execution as we advance toward the Phase 3 topline data readout for navacaprant in the fourth quarter,” said Henry Gosebruch, president and chief executive officer, Neumora. “We are well-positioned to achieve multiple potential value creating catalysts in 2024 and 2025 across our strong pipeline, which is focused on alleviating the substantial unmet medical need in neuropsychiatric and neurodegenerative diseases with multiple targets that are supported by strong biological rationale and clinical validation.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Neumora Therapeutics falls 23% after FDA clinical hold of Phase 1 NMRA-266 study
- Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
- Neumora Therapeutics announces clinical hold of Phase 1 NMRA-266 study
- Neumora weakness amid lock-up expiration a buying opportunity, says RBC Capital